Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
BioPorto Diagnostics and QIAGEN have successfully validated the use of BioPorto’s gRAD lateral flow platform on QIAGENS’s ESEQuant LR3 Lateral Flow System.
By combining gRAD with the ESEQuant LRS system, this platform, provides a powerful and versatile toolbox for rapid development of lateral flow-based assays. This toolbox is well suited in the constantly shifting lateral flow market space, where the demand for new applications in human diagnostics, veterinary diagnostics, food industry and environmental/agriculture testing is rapidly increasing.
Jan Kuhlmann Andersen, COO of BioPorto, commented: “With the gRAD platform BioPorto Diagnostics has the ability to offer assay developers across several industries contract development of their assay development. Through the combination of gRAD and the ESEQuant LRS system, BioPorto now has a complete assay development process in place to test across above mentioned business segments.”
Read more about the gRAD lateral flow technology and the ESEQuant LR3 Lateral Flow technology.
www.bioporto.com/Products/Product-by-category/Lateral-flow.aspx
http://www.lateralflowreader.com/new-powerful-option-esequant-lr3-grad/
For further information, please contact:
Peter Mørch Eriksen, CEO
Gry Husby Larsen, General Counsel
Telephone +45 4529 0000, e-mail [email protected]
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/3275dac8-8136-4c84-a74d-b229acccc5eb
